Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. - Archive ouverte HAL Access content directly
Journal Articles Cancer Chemotherapy and Pharmacology Year : 2014

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

(1) , (2) , (2) , (3) , (3) , (1) , (2)
1
2
3

Abstract

INTRODUCTION: In the literature, data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68-year-old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m(2) cetuximab. MATERIAL AND METHODS: Pharmacokinetic parameters after the first dose, including dose-normalised AUC from time zero to day 7, clearance, elimination half-life (t 1/2), were estimated using trapezoidal non-compartmental methods and compared to pharmacokinetic data from a study population with normal kidney function. RESULTS: The results showed that the pharmacokinetics of cetuximab in this patient with renal failure was similar to that with adequate renal function. CONCLUSION: This study suggests that cetuximab can be safely used in cancer patients with renal impairment without dose adjustment.
Fichier principal
Vignette du fichier
Submitted_manuscript_-_pharmacokinetics_and_safety_of_cetuximab_in_a_patient_with_renal_dysfunction.pdf (94.17 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-00992023 , version 1 (16-05-2014)

Identifiers

Cite

L. L. Krens, J. M. Baas, M. C. Verboom, G. Paintaud, C. Desvignes, et al.. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.. Cancer Chemotherapy and Pharmacology, 2014, epub ahead of print. ⟨10.1007/s00280-014-2462-4⟩. ⟨hal-00992023⟩

Collections

UNIV-TOURS CNRS
294 View
977 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More